This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, H. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Yamada, H. Articles by Horiuchi, M. Related Collections ACE/Angiotension receptors Animal models of human disease Smooth muscle proliferation and differentiation

(Hypertension. 1999;33:1414-1419.)
© 1999 American Heart Association, Inc.

Scientific Contributions

AT₂ Receptor and Vascular Smooth Muscle Cell Differentiation in Vascular Development

Hiroyuki Yamada; Masahiro Akishita; Masaaki Ito; Kouichi Tamura; Laurent Daviet; Jukka Y. A. Lehtonen; Victor J. Dzau; Masatsugu Horiuchi

From Cardiovascular Research, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Masatsugu Horiuchi, MD, PhD, Department of Medical Biochemistry, Ehime University School of Medicine, Sigenobu, Onsen-gun, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—The angiotensin II type 2 (AT₂) receptor is transiently expressed at late gestation in the fetal vasculature, but its expression rapidly declines after birth. We have previously demonstrated that the expression of this receptor mediates decline in vascular DNA synthesis that occurs at this stage of vascular development. To examine further the role of the AT₂ receptor in vasculogenesis, we have focused on the effect of the AT₂ receptor on vascular smooth muscle cell (VSMC) differentiation. In this study, we examined the time-dependent expression of differentiation markers for VSMCs in the aorta of wild-type and AT₂ receptor–null mice. -Smooth muscle actin was expressed at the early stage of differentiation and exhibited unchanged expression before and after the peak of AT₂ receptor expression, which was observed at embryonic day 20, neonatal day 1, and thereafter. No difference in -smooth muscle actin expression was observed between the wild-type and AT₂ receptor–null mice. In contrast, the mRNA levels for calponin, expressed in the late stage of VSMC differentiation, were significantly higher in the wild-type mouse aorta as compared with the AT₂ receptor–null mice, which correlates with expression of the AT₂ receptor. Moreover, the protein levels of calponin and high-molecular-weight caldesmon (h-caldesmon) showed lower expression in the aorta of AT₂ receptor knockout mice at 2 and 4 weeks after birth. Taken together, our results suggest that the AT₂ receptor promotes vascular differentiation and contributes to vasculogenesis.

Key Words: angiotensin • cell differentiation • receptors, angiotensin II • muscle, smooth, vascular • human development

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Angiotensin II (Ang II), a key regulator of cardiovascular homeostasis, exerts various actions in its diverse target tissues, that controls vascular tone, hormone secretion, tissue growth, and neuronal activity. Two major isoforms of the Ang II receptor, type 1 (AT₁) and type 2 (AT₂), have been defined on the basis of their ligand selectivity. Most of the known effects of Ang II in the adult tissues are attributable to the AT₁ receptor. The AT₂ receptor is abundantly and widely expressed in fetal tissues,^{1 2 3} and its expression declines rapidly after birth, which suggests that the AT₂ receptor is involved in growth, development, and/or differentiation.

The expression of the AT₂ receptor in rat fetal blood vessel is "turned on" at late gestation (embryonic days 16 to 21) and in the early neonatal period but decreases rapidly to very low levels in the adult vessel.^{4 5} We have demonstrated that this receptor exerts growth-modulatory effects in vascular smooth muscle cells (VSMCs) such as the inhibition of DNA synthesis and the induction of apoptosis.^{4 6} The spatial and temporal patterns of the rat vascular AT₂ receptor expression, together with the growth modulatory action, have led us to hypothesize that this receptor plays an important role in vascular development and remodeling in late gestation. Indeed, pharmacological blockade of the vascular AT₂ receptor by use of the specific antagonist PD123319 in the rat fetus during rat embryonic days 16 to 21 (E16-E21) has resulted in decreased aortic DNA synthesis, which supports a contribution of the AT₂ receptor to vascular development.

We and others have obtained, by use of a homologous recombination, AT₂ receptor knockout mouse strains that exhibit enhanced pressor response to acute Ang II infusion as compared with the wild-type strain.^{7 8} Because the vascular AT₂ receptor is minimally expressed at the time the blood pressure and Ang II infusion studies were performed, the data suggest that the transient and developmentally regulated AT₂ receptor expression exerts a long-term effect on blood pressure, possibly through its influence on vascular structure and/or function. These results support the notion that the AT₂ receptor modulates the growth of the developing blood vessel and thus contributes to vascular remodeling in late gestation.

Little is known about the ability of the AT₂ receptor to modulate VSMC differentiation. Recent studies suggest that AT₂ receptor activation may enhance differentiation in PC12W cells, a rat pheochromocytoma cell line,^{9 10 11} and NG 108-15 cells.¹² The middle-sized neurofilament subunit expression was reduced in PC12W cells by AT₂ receptor stimulation.¹⁰ In quiescent PC12W cells, AT₂ receptor stimulation upregulated microtubule components and polymerized ß-tubulin and MAP2, but downregulated MAP1B protein levels and, in PC12W cells differentiated by nerve growth factor, AT₂ receptor stimulation elevated polymerized ß-tubulin and reduced MAP1B.¹¹ The morphological changes of AT₂ receptor–mediated neurite outgrowth in NG 108-15 cells were correlated with an increase in the level of polymerized tubulin and in the level of the microtubule-associated protein.¹¹ These results suggest a specific role of AT₂ receptors in neuronal cell differentiation through regulation of the cytoskeleton. Thus it is conceivable that the AT₂ receptor exerts a similar effect on smooth muscle cell differentiation. The AT₂ receptor–null mouse model provides a unique opportunity to address the physiological role of the AT₂ receptor. According to this hypothesis, activation of the AT₂ receptor would facilitate VSMC differentiation in the wild-type animal, whereas the disruption of the AT₂ receptor in the knockout animals will result in the delayed differentiation of VSMCs.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
Female mice heterozygous for the AT₂ receptor mutant allele⁷ were mated with WT FVB/N male mice (Jackson Laboratory, Bar Harbor, Maine). Pregnant mice were killed with an overdose of anesthesia, and the fetuses were dissected from uterine decidua. The day when a vaginal plug was observed was considered E1. In addition, postnatal and 2-week-old, 4-week-old, and 8-week-old male mice, which were obtained by the same mating as the fetuses, were used. These fetuses and postnatal mice, back-crossed for 6 generations into the FVB/N background, had 98% FVB/N and 2% 129/SV background. Animal genotyping was performed as previously described,⁷ with the use of body or tail genomic DNA samples. The animals were housed in a room in which light was controlled (12 hours on, 12 hours off) and room temperature was kept at 22°C. They were given standard diet and water ad libitum. All experimental procedures were approved and carried out in accordance with the guideline of the Harvard Medical Area Standing Committee on Animals.

Immunoblot Analysis
Mice were anesthetized with an intraperitoneal injection of ketamine (70 mg/kg) and xylazine (4 mg/kg); the thorax was opened and the aorta was removed. The connective tissues around the thoracic aorta were carefully dissected away in ice-cold phosphate-buffered saline (pH 7.40) under stereomicroscopy. Tissue samples were homogenized in 50 mmol/L Tris-HCl buffer, pH 7.5, which contained 150 mmol/L NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L PMSF, 1.5 µmol/L aprotinin, 5.5 µmol/L leupeptin, and 5.5 µmol/L pepstatin A. Tissue lysates were centrifuged at 10 000g for 20 minutes, boiled in Laemli loading buffer for 3 minutes, resolved by 8% SDS-PAGE, electroblotted onto nitrocellulose membrane, and immunoblotted with antibodies against high-molecular-weight caldesmon (h-caldesmon) (clone C21),¹³ calponin (clone hCP),¹⁴ or -smooth muscle actin (-SM actin) (clone 1A4)¹⁵ (Sigma Chemical Co). Antibodies were detected by horseradish peroxidase–linked secondary antibody with the use of an enhanced chemiluminescence system (Amersham Life Science Inc). Densitometric analysis was performed by scanning densitometer (GS300, Hoeffer) and NIH image software.

Reverse Transcription–Polymerase Chain Reaction
Pregnant mice were anesthetized with an intraperitoneal injection of ketamine (70 mg/kg) and xylazine (4 mg/kg) at 13, 15, 18, and 20 days of gestation (E13, E15, E18, and E20). Fetuses were removed and their thoracic aortas were carefully excised under stereomicroscopy, frozen in liquid nitrogen, and kept at -80°C before use. Aortas were also prepared from mice at 1, 7, 14, and 28 days after birth. Total RNA was prepared from 4 to 7 pooled thoracic aortas for each group with the use of TRIzol reagent (GIBCO BRL). Total RNA was first treated with RNAse-free DNAse (0.02 U/µL). After treatment for 5 minutes at 94°C, the samples were subjected to reverse transcription with random hexamer primers and reverse transcriptase (GeneAmp RNA PCR Kit, Perkin Elmer). We performed other sets of reverse transcription–polymerase chain reaction (RT-PCR) without RNA samples to confirm that there was no artificial amplification caused by the contaminations in the reagents. PCR primers were as follows: calponin, 5'-CACCAACAAGTTTGCCAG-3' and 5'-TGTGTCGCAGTGTTCCAT-3'¹⁴ ; -SM actin, 5'-GAGAAGCCCAGCCAGTCG-3' and 5'-CTCTTGCTCTGGGCTTCA-3'¹⁶ ; AT₁ receptor, 5'-GGAAACAGCTTGGTGGTG-3' and 5'-CTGAATTTCATAAGCCTTCTT-3'¹⁷ ; AT₂ receptor, 5'-AGTGCATGCGGGAGCTG-3' and 5'-GACAACAAAACAGTGAG-3'¹⁸ ; and GAPDH, 5'-ATGGTGAAGGTCGGTGTG-3' and 5'-ACCAGTGGATGCAGGGAT-3'.¹⁹ PCR reactions for -SM actin, calponin, or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were performed with 25 cycles of 1 minute of denaturation at 94°C, 1 minute of annealing at 53°C, and 2 minutes of extension at 72°C followed by 10 minutes of final extension step. PCR reactions for AT₁ or AT₂ receptors were carried out with 30 cycles. We observed a linear increase in amplification of PCR products with an increased amount of RNA up to 2 µg and as well as the increase in PCR cycles until 30 cycles for -SM actin, calponin, or GAPDH and until 35 cycles for AT₁ and AT₂ receptors. PCR products were separated by 1% agarose gel electrophoresis. To verify the identity of the PCR products, we sequenced PCR products and confirmed that the sequences of PCR products matched up to the predicted sequences.

Blood Pressure Measurements
Male mice were anesthetized and a PE10 tube (Becton Dickinson) was inserted into the left common carotid artery. The next day, the PE50 tube was connected to the carotid artery cannula. The other end of the tube was connected to the blood pressure transducer (model TRN050, Kent Scientific Corp), which was connected to a transducer amplifier (model ETH-400, CB Sciences, Inc) and a MacLab 4/s (Division of AD Instruments, Inc). Blood pressure and heart rate were measured with rats in a conscious, unrestrained condition.

Data Analysis
All values are expressed as mean±SE. Statistical significance for the developmental changes in differentiation marker expression in each strain of mice was assessed by ANOVA followed by Bonferroni test. Student's t tests were used for statistical comparisons between 2 strains of mice. A value of P<0.05 was considered to be significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
To study the effect of AT₂ receptor gene disruption on VSMC differentiation in the aorta, we examined the VSMC-specific contractile proteins as differentiation markers at different ages before birth and up to 8 weeks after birth. As shown in Figure 1, the protein contents of h-caldesmon and calponin increase age dependently. These protein levels were significantly lower in AT₂ receptor–null mice than those in wild-type mice at 2 and 4 weeks of age (Figure 1, A, B, and C). Interestingly, at 8 weeks of age there were no differences in these marker proteins between both strains. On the other hand, there were no differences in -SM actin expression between the strains throughout development (Figure 1, A and D).

View larger version (33K): [in this window] [in a new window]   Figure 1. Developmental changes in expression of h-caldesmon, calponin, and -SM actin in thoracic aorta. Tissue lysates were prepared from thoracic aortas from AT2-null (Null) and wild-type (WT) mice at the ages of 2, 4, and 8 weeks, separated on SDS/PAGE, electroblotted on the nitrocellulose membrane, and immunoblotted with h-caldesmon, calponin, or -SM actin antibodies. A, Representative data obtained from 8 different experiments. B, C, and D, Signal density is represented as percentage of the value obtained in wild-type mice at 8 weeks of age. Values are expressed as mean±SE obtained from 8 animals in each group. *P<0.05 vs wild-type mice at the same age.

Next, we examined the developmentally regulated calponin, -SM actin, and AT₁ and AT₂ receptor mRNA expressions in the fetal aorta by RT-PCR. To show the linear increase of RT-PCR products with increased amounts of RNA by use of our PCR conditions described in Methods, total RNA (2, 1, or 0.5 µg of RNA) prepared from thoracic aorta of wild-type mice at the age of E20 was subjected to RT-PCR for AT₁ receptor, AT₂ receptor, calponin, -SM actin, and GAPDH (Figure 2). In the following experiments shown in Figure 3, we applied 1 µg RNA to RT-PCR. The mouse AT₁ receptor mRNA is expressed at relatively constant levels from the initial age tested (E13) throughout development both in AT₂ receptor–null and wild-type mice (Figure 3A). The AT₂ receptor mRNA expression was observed at E13, increased thereafter, and rapidly declined after birth (Figure 3A). As shown in Figure 3B, the mRNA expression of calponin in wild-type mice was observed at E13, associated with the onset of AT₂ receptor mRNA expression, and increased thereafter. The expression and the developmental increase in calponin mRNA expression in AT₂ receptor–null mice were significantly delayed. Aortic calponin mRNA expression in the wild-type and AT₂ receptor–null mouse appeared to be similar at 14 and 28 days after birth (Figure 3C). In contrast, -SM actin mRNA level did not differ throughout development between the 2 strains.

View larger version (69K): [in this window] [in a new window]   Figure 2. RT-PCR showing semiquantitative evaluation of mRNAs for AT1 receptor, AT2 receptor, calponin, -SM actin, and GAPDH. Total RNA was prepared from thoracic aorta of wild-type mice at the age of E20; 2 µg (lane 1), 1 µg (lane 2), or 0.5 µg (lane 3) of RNA was subjected to RT-PCR. M, 100-bp ladder DNA marker.

View larger version (35K): [in this window] [in a new window]   Figure 3. Developmental changes in mRNA expression of (A) AT1 and AT2 receptors, (B) calponin, -SM actin, and AT2 receptor, and (C) calponin in mouse aorta. Total RNA (1 µg) was prepared from thoracic aortas of AT2 receptor–null (Null) and wild-type (WT) mice at the ages of E13, E15, E18, E20, N1, 1, 2, and 4 weeks and subjected to RT-PCR. Results show representative data of 3 separate experiments. GAPDH was used as internal control42 43 to standardize the amount of total RNA used.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
AT₂ receptor is expressed in fetal aorta during late gestation; its expression decreases rapidly after birth, and the AT₂ receptor is reexpressed in vascular injury.⁴ We have demonstrated that pharmacological blockade of the AT₂ receptor in fetal rats E16 to E21 by use of the specific antagonist PD123319 has resulted in decreased DNA synthesis of the developing aorta.⁴ Accordingly, we have hypothesized that the AT₂ receptor is involved with vascular development. In this study we examined the possibility that the AT₂ receptor modulates VSMC differentiation and plays a role in vasculogenesis. Our data demonstrated that the protein levels of h-caldesmon and calponin in VSMC in thoracic aorta of AT₂ receptor–null mice were significantly lower than those in wild-type mice up to 4 weeks of age, whereas the expression of -SM actin did not show any difference between the 2 strains. Expressions of h-caldesmon and calponin as well as -SM actin are developmentally regulated in VSMC.^{20 21 22} -SM actin appears in the early stage in vasculogenesis, whereas the expressions of h-caldesmon and calponin begin later and have been used as markers of VSMC differentiation in the late stage of vasculogenesis.

To examine the relation of AT₂ receptor expression with VSMC differentiation, we examined h-caldesmon, calponin, -SM actin, and AT₂ receptor expression in fetal and neonatal mice. Consistent with previous data on the rat,^{4 5} we demonstrated that mouse AT₂ receptor mRNA expression is low during early development (E13-E15) but increases significantly during later stage of development (E18-E20) and in the neonate (1 day after birth), whereas the AT₁ receptor is constantly expressed through early embryonic stage after birth. The mRNA expression of calponin in wild-type mice aorta was "switched on" at E13 to E15 in both strains of mouse. The level of calponin mRNA increased rapidly thereafter in wild-type mouse aorta, whereas calponin mRNA in the AT₂ receptor–null mouse was significantly lower and reached similar levels of calponin mRNA in the wild-type mouse at 14 days after birth. These results suggest that the level of expression of calponin is closely associated with the AT₂ receptor expression in the fetal aorta. Moreover, we demonstrated that the protein levels of calponin and h-caldesmon are significantly higher in the AT₂ receptor–null mouse aorta up to 4 weeks after birth. In contrast, we did not observe any significant difference in -SM actin mRNA expression in aorta between the 2 strains during development. -SM actin expression was already observed at E13, when the AT₂ receptor was not expressed, which suggests that -SM actin is not regulated by the AT₂ receptor. These findings suggest strongly that the AT₂ receptor plays a role in the phenotypic differentiation of VSMC, especially in the late stage of gestation.

We did not directly measure VSMC differentiation or vasculogenesis. h-caldesmon and calponin, thin filament–associated proteins, have been suggested to modulate smooth muscle contractility.^{23 24 25 26} Binding of h-caldesmon and calponin to actin inhibits actomyosin ATPase, which is necessary for initiation of contraction of VSMC and appears to be involved in vascular contraction in vivo.^{27 28 29} Moreover, h-caldesmon and calponin have been reported to inhibit contraction by providing a basal resting inhibition of vascular tone in smooth muscle cells.^{24 26} To examine the possibility that delayed expression of h-caldesmon and calponin in AT₂ receptor–null mice influences the resting vascular tone and blood pressure, we measured blood pressure and heart rate in conscious mice at 4 and 8 weeks of age. Basal mean blood pressure in 4-week-old AT₂ receptor–null mice was significantly higher than that in wild-type mice (105.2±4.5 versus 87.5±3.9 mm Hg, n=10, P<0.05), whereas there was no difference in blood pressure at 8 weeks of age (109.2±5.7 versus 107.7±4.8 mm Hg, n=10). There were no significant differences in heart rate between both strains. Mean blood pressure of AT₂ receptor–null mice was significantly higher compared with wild-type mice at the age of 4 weeks, when h-caldesmon and calponin contents are lower in AT₂ receptor–null mice. Along with the increase in h-caldesmon and calponin in AT₂ receptor–null mouse aorta, the blood pressure difference disappeared at age 8 weeks. These results suggest the possibility that the delayed expression of these VSMC markers in AT₂ receptor null–mice plays some role in vasculogenesis and influence vascular contractility.

We have demonstrated that the AT₂ receptor exerts antigrowth and proapoptotic effects in VSMC in vitro and in vivo.^{4 6 30} The antigrowth effect of the AT₂ receptor in endothelial cells and cardiomyocytes have also been reported.^{31 32} In this report, we postulate that the AT₂ receptor enhances the differentiation of VSMC in aorta. Indeed, it has been reported that the AT₂ receptor promotes differentiation of neuronal cells through regulation of cytoskeletal proteins.^{9 10 11 12} The AT₂ receptor has been reported to stimulate protein tyrosine phosphatase (PTPase) activity,^{4 6 33 34 35 36 37} which plays an essential role in hematopoietic cell differentiation.³⁸ We have reported that the intracellular third loop of the AT₂ receptor is important for its PTPase activation.³⁰ Interestingly, recent studies suggest that dopamine receptors, which have a similar amino acid motif in the intracellular third loop,³⁹ promotes morphogenesis of developing neurons.^{40 41} These findings suggest a possible mechanism whereby AT₂ receptor–regulated PTPase is involved in the differentiation of VSMC. Our results also suggest that AT₂ receptor stimulation did not modify the expression of housekeeping genes such as GAPDH.^42,43 In summary, our results suggest that the AT₂ receptor participates in mouse vasculogenesis.

	Acknowledgments

 
This work was supported by National Institutes of Health grants HL-46631, HL-35252, HL-35610, HL-48638, HL-07708, and HL-58616 and a grant from the Longwood Foundation for Translational Research. Dr Dzau is a recipient of NIH MERIT Award HL-35610.

Received September 21, 1998; first decision October 15, 1998; accepted February 2, 1999.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT₂ receptors in the developing rat fetus. J Clin Invest. 1991;88:921–933.

2. Tsutsumi K, Stromberg C, Viswanathan M, Saavedra JM. Angiotensin-II receptor subtypes in fetal tissues of the rat: autoradiography, guanine nucleotide sensitivity, and association with phosphoinositide hydrolysis. Endocrinology. 1991;129:1075–1082.[Abstract/Free Full Text]

3. Millan MA, Jacobowitz DM, Aguilera G, Catt KJ. Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci U S A. 1991;88:11440–11444.[Abstract/Free Full Text]

4. Nakajima M, Hutchinson H, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2(AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663–10667.[Abstract/Free Full Text]

5. Shanmugam S, Corvol P, Gasc JM. Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Hypertension. 1996;28:91–97.[Abstract/Free Full Text]

6. Yamada T, Akishita M, Pollman M, Gibbons GH, Dzau VJ, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin type 1 receptor action: an in vitro gene transfer study. Life Sci. 1998;63:289–295.

7. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature. 1995;377:744–747.[Medline] [Order article via Infotrieve]

8. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BLM, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748–750.[Medline] [Order article via Infotrieve]

9. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol. 1996;122:59–67.[Medline] [Order article via Infotrieve]

10. Gallinat S, Csikos T, Meffert S, Herdegen T, Stoll M, Unger T. The angiotensin AT2 receptor down-regulates neurofilament M in PC12W cells. Neurosci Lett. 1997;227:29–32.[Medline] [Order article via Infotrieve]

11. Stroth U, Meffert S, Gallinat S, Unger T. Angiotensin II and NGF differentially influence microtubule proteins in PC12W cells: role of the AT2 receptor. Brain Res Mol Brain Res. 1998;53:187–195.[Medline] [Order article via Infotrieve]

12. Laflamme L, Gasparo M, Gallo JM, Payet MD, Gallo-Payet N. Angiotensin II induction of neurite outgrowth by AT2 receptor in NG108–15 cells. J Biol Chem. 1996;271:22729–22735.[Abstract/Free Full Text]

13. Ehler E, Jat PS, Noble MD, Citi S, Draeger A. Vascular smooth muscle cells of H-2Kb-tsA58 transgenic mice: characterization of cell lines with distinct properties. Circulation. 1995;92:3289–3296.[Abstract/Free Full Text]

14. Miano JM, Olson EN. Expression of the smooth muscle cell calponin gene marks the early cardiac and smooth muscle cell lineages during mouse embryogenesis. J Biol Chem. 1996;271:7095–7103.[Abstract/Free Full Text]

15. Takahashi Y, Imanaka T, Takano T. Spatial and temporal pattern of smooth muscle cell differentiation during development of the vascular system in the mouse embryo. Anat Embryol. 1996;194:515–526.[Medline] [Order article via Infotrieve]

16. Min BH, Strauch AR, Foster DN. Nucleotide sequence of a mouse vascular smooth muscle alpha-actin cDNA. Nucleic Acids Res. 1988;16:10374.[Free Full Text]

17. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ. Cloning, characterization, and expression of 2 angiotensin receptor (AT1) isoforms from the mouse genome. Biochem Biophys Res Comm. 1992;185:253–259.[Medline] [Order article via Infotrieve]

18. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Comm. 1993;197:393–399.[Medline] [Order article via Infotrieve]

19. Sabath DE, Broome HE, Prystowsky MB. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced transcript in a cloned T-helper lymphocyte. Gene. 1990;91:185–191.[Medline] [Order article via Infotrieve]

20. Ueki N, Sobue K, Kanda K, Hada T, Higashino K. Expression of high and low molecular weight caldesmons during phenotypic modulation of smooth muscle cells. Proc Natl Acad Sci U S A. 1987;84:9094–9053.[Abstract/Free Full Text]

21. Frid MG, Shekhonin BV, Koteliansky VE, Glukhova MA. Phenotypic change of human smooth muscle cells during development: late expression of heavy caldesmon and calponin. Dev Biol. 1992;153:185–193.[Medline] [Order article via Infotrieve]

22. Glukhova MA, Frid MG, Koteliansky VE. Developmental changes in expression of contractile and cytoskeletal proteins in human aortic smooth muscle. J Biol Chem. 1990;265:13042–13046.[Abstract/Free Full Text]

23. Barany K, Polyak E, Barany M. Involvement of calponin and caldesmon in sustained contraction of arterial smooth muscle. Biochem Biophys Res Comm. 1992;187:847–852.[Medline] [Order article via Infotrieve]

24. Katsuyama H, Wang CLA, Morgan KG. Regulation of vascular smooth muscle tone by caldesmon. J Biol Chem. 1992;267:14555–14558.[Abstract/Free Full Text]

25. Gerthoffer WT, Pohl J. Caldesmon and calponin phosphorylation in regulation of smooth muscle contraction. Can J Physiol Pharmacol. 1994;72:1410–1414.[Medline] [Order article via Infotrieve]

26. Itoh T, Suzuki A, Watanabe Y, Mino T, Naka M, Tanaka T. A calponin peptide enhances Ca2+ sensitivity of smooth muscle contraction without affecting myosin light chain phosphorylation. J Biol Chem. 1995;270:20400–20403.[Abstract/Free Full Text]

27. Sobue K, Takahashi K, Wakabayashi I. Caldesmon 150 regulates the tropomyosin-enhanced actin-myosin interaction in gizzard smooth muscle. Biochem Biophys Res Commun. 1985;132:645–651.[Medline] [Order article via Infotrieve]

28. Winder SJ, Walsh MP. Structure and functional characterization of calponin fragments. Biochem Int. 1990;22:335–341.[Medline] [Order article via Infotrieve]

29. Pfitzer G, Zeugner C, Troschka M, Chalovich JM. Caldesmon and 20-kDa actin-binding fragment of caldesmon inhibit tension development in skinned gizzard muscle fiber bundles. Proc Natl Acad Sci U S A. 1993;90:5904–5908.[Abstract/Free Full Text]

30. Hayashida W, Horiuchi M, Dzau VJ. Intracellular third loop domain of angiotensin II type-2 receptor. J Biol Chem. 1996;271:21985–21992.[Abstract/Free Full Text]

31. Stoll M, Steckelings M, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–657.

32. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin receptors in angiotensin II–induced cardiomyocyte hypertrophy. Hypertension. 1996;28:635–640.[Abstract/Free Full Text]

33. Bottari SP, King IN, Reichlin S, Dahlstroem I, Lydon N, de Gasparo M. The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Comm. 1992;183:206–211.[Medline] [Order article via Infotrieve]

34. Buisson B, Laflamme L, Bottari SP, de Gasparo M, Gallo-Payet N, Payet MD. A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108–15 cells. J Biol Chem. 1995;270:1670–1674.[Abstract/Free Full Text]

35. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A. 1996;93:156–160.[Abstract/Free Full Text]

36. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J. 1997;325:449–454.

37. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem. 1997;272:19022–19026.[Abstract/Free Full Text]

38. Sorio C, Melotti P, D'Arcangelo D, Mendrola J, Calabretta B, Croce CM, Huebner K. Receptor protein tyrosine phosphatase gamma, Ptp gamma, regulates hematopoietic differentiation. Blood. 1997;90:49–57.[Abstract/Free Full Text]

39. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt PE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of 7-transmembrane receptor. J Biol Chem. 1993;268: 24539–24542.

40. Schmidt U, Beyer C, Oestreicher AB, Reisert I, Schilling K, Pilgrim C. Activation of dopaminergic D1 receptors promotes morphogenesis of developing striatal neurons. Neuroscience. 1996;74:453–460.[Medline] [Order article via Infotrieve]

41. Reinoso BS, Undie AS, Levitt P. Dopamine receptors mediate differential morphological effects on cerebral cortical neurons in vitro. J Neurosci Res. 1996;43:439–453.[Medline] [Order article via Infotrieve]

42. Shanahan CM, Weissberg PL, Metcalfe JC. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ Res. 1993;73:193–204.[Abstract]

43. Jain MK, Layne MD, Watanabe M, Chin MT, Feinberg MW, Sibinga NE, Hsieh CM, Yet SF, Stemple DL, Lee ME. In vitro system for differentiating pluripotent neural crest cells into smooth muscle cells. J Biol Chem. 1998;273:5993–5996.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF]

				A. D'Amore, M. J. Black, and W. G. Thomas The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy Hypertension, December 1, 2005; 46(6): 1347 - 1354. [Abstract] [Full Text] [PDF]

				R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367. [Abstract] [Full Text] [PDF]

				M. Okumura, M. Iwai, A. Ide, M. Mogi, M. Ito, and M. Horiuchi Sex Difference in Vascular Injury and the Vasoprotective Effect of Valsartan Are Related to Differential AT2 Receptor Expression Hypertension, September 1, 2005; 46(3): 577 - 583. [Abstract] [Full Text] [PDF]

				N. Hattan, H. Kawaguchi, K. Ando, E. Kuwabara, J. Fujita, M. Murata, M. Suematsu, H. Mori, and K. Fukuda Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice Cardiovasc Res, February 1, 2005; 65(2): 334 - 344. [Abstract] [Full Text] [PDF]

				D. Perlegas, H. Xie, S. Sinha, A. V. Somlyo, and G. K. Owens ANG II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H96 - H102. [Abstract] [Full Text] [PDF]

				A. Daugherty, D. L. Rateri, H. Lu, T. Inagami, and L. A. Cassis Hypercholesterolemia Stimulates Angiotensin Peptide Synthesis and Contributes to Atherosclerosis Through the AT1A Receptor Circulation, December 21, 2004; 110(25): 3849 - 3857. [Abstract] [Full Text] [PDF]

				O. Johren, A. Dendorfer, and P. Dominiak Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res, June 1, 2004; 62(3): 460 - 467. [Abstract] [Full Text] [PDF]

				L. Gendron, J.-F. Oligny, M. D. Payet, and N. Gallo-Payet Cyclic AMP-independent Involvement of Rap1/B-Raf in the Angiotensin II AT2 Receptor Signaling Pathway in NG108-15 Cells J. Biol. Chem., January 31, 2003; 278(6): 3606 - 3614. [Abstract] [Full Text] [PDF]

				S. P. Bagby, L. S. LeBard, Z. Luo, B. E. Ogden, C. Corless, E. D. McPherson, and R. C. Speth ANG II AT1 and AT2 receptors in developing kidney of normal microswine Am J Physiol Renal Physiol, October 1, 2002; 283(4): F755 - F764. [Abstract] [Full Text] [PDF]

				M. Stoll, A. W.A. Hahn, U. Jonas, Y. Zhao, B. Schieffer, J. W. Fischer, and T. Unger Identification of a Zinc Finger Homoeodomain Enhancer Protein After AT2 Receptor Stimulation by Differential mRNA Display Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 231 - 237. [Abstract] [Full Text] [PDF]

				C. Berry, R. Touyz, A. F. Dominiczak, R. C. Webb, and D. G. Johns Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2337 - H2365. [Abstract] [Full Text] [PDF]

				L. Wu, M. Iwai, H. Nakagami, Z. Li, R. Chen, J. Suzuki, M. Akishita, M. de Gasparo, and M. Horiuchi Roles of Angiotensin II Type 2 Receptor Stimulation Associated With Selective Angiotensin II Type 1 Receptor Blockade With Valsartan in the Improvement of Inflammation-Induced Vascular Injury Circulation, November 27, 2001; 104(22): 2716 - 2721. [Abstract] [Full Text] [PDF]

				M. Brede, K. Hadamek, L. Meinel, F. Wiesmann, J. Peters, S. Engelhardt, A. Simm, A. Haase, M. J. Lohse, and L. Hein Vascular Hypertrophy and Increased P70S6 Kinase in Mice Lacking the Angiotensin II AT2 Receptor Circulation, November 20, 2001; 104(21): 2602 - 2607. [Abstract] [Full Text] [PDF]

				R. Bautista, A. Sanchez, J. Hernandez, A. Oyekan, and B. Escalante Angiotensin II Type AT2 Receptor mRNA Expression and Renal Vasodilatation Are Increased in Renal Failure Hypertension, September 1, 2001; 38(3): 669 - 673. [Abstract] [Full Text] [PDF]

				M. El Mabrouk, R. M. Touyz, and E. L. Schiffrin Differential ANG II-induced growth activation pathways in mesenteric artery smooth muscle cells from SHR Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H30 - H39. [Abstract] [Full Text] [PDF]

				L. R. Green Programming of Endocrine Mechanisms of Cardiovascular Control and Growth Reproductive Sciences, April 1, 2001; 8(2): 57 - 68. [Abstract] [PDF]

				M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, and Th. Unger International Union of Pharmacology. XXIII. The Angiotensin II Receptors Pharmacol. Rev., September 1, 2000; 52(3): 415 - 472. [Abstract] [Full Text] [PDF]

				A. M. Devlin, J. S. Clark, J. L. Reid, and A. F. Dominiczak DNA Synthesis and Apoptosis in Smooth Muscle Cells From a Model of Genetic Hypertension Hypertension, July 1, 2000; 36(1): 110 - 115. [Abstract] [Full Text] [PDF]

				S. Gallinat, S. Busche, M. K. Raizada, and C. Sumners The angiotensin II type 2 receptor: an enigma with multiple variations Am J Physiol Endocrinol Metab, March 1, 2000; 278(3): E357 - E374. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamada, H. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Yamada, H. Articles by Horiuchi, M. Related Collections ACE/Angiotension receptors Animal models of human disease Smooth muscle proliferation and differentiation